Viemed Healthcare Announces Record 2023 Financial Results

 

Viemed Healthcare, Inc. (the "Company" or "Viemed") (NASDAQ:VMD), a national leader in respiratory care and technology-enabled home medical equipment services, announced today that it has reported its financial results for the three months and year ended December 31, 2023.

 

  Operational highlights (all dollar amounts are USD):  

 
  • Net revenues for the quarter ended December 31, 2023 reached a new Company record of $50.7 million representing an increase of $13.2 million, or 35%, over net revenues reported for the comparable quarter ended December 31, 2022. Total net revenues for the year ended December 31, 2023 were a record-breaking $183.0 million, an increase of $44.2 million, or 32%, over the year ended December 31, 2022.
  •  
  • Net income for the quarter ended December 31, 2023 totaled $3.5 million, an increase of 43% over net income reported for the comparable quarter ended December 31, 2022. Net income for the year ended December 31, 2023 totaled $10.2 million, an increase of 65% over the year ended December 31, 2022, marking the Company's seventh consecutive year of positive net income.
  •  
  • Adjusted EBITDA for the quarter and year ended December 31, 2023 totaled $12.8 million and a record $43.1 million, respectively. A reconciliation of reported non-GAAP financial measures to their most directly comparable U.S. GAAP financial measures can be found in the tables accompanying this press release.
  •  
  • Net cash provided by operating activities for the year ended December 31, 2023 totaled $45.2 million, an increase of $17.5 million, or 62.9%, over the year ended December 31, 2022. Free Cash Flow for the year ended December 31, 2023 totaled $19.1 million, an increase of $14.3 million, or 294%, over the year ended December 31, 2022.
  •  
  • As of December 31, 2023, the Company maintains a strong cash balance of $12.8 million ($16.9 million at December 31, 2022), and an overall working capital balance of $6.2 million ($20.9 million at December 31, 2022). Long-term debt as of December 31, 2023 amounted to $6.0 million (the company had no long-term debt at December 31, 2022). After successfully completing an approximately $30 million acquisition during 2023, the Company ended the year with no net debt and has approximately $53 million available under existing credit facilities.
  •  
  • The Company expects to generate net revenues of approximately $49.7 million to $51.0 million during the first quarter of 2024 and assumes that the 75/25 blended Medicare reimbursement rate adjustment in non-rural, non-competitive bid areas is not extended.
  •  

"We're thrilled to announce another exceptional year of financial performance at Viemed, marked by robust double-digit annual growth and sustained profitability," said Casey Hoyt, Viemed's CEO. "We are particularly pleased with the Company's capacity to generate free cash flow, enabling us to fuel continued strong growth. This underscores the effectiveness of our strategic initiatives and the dedication of our entire team. These accomplishments reaffirm our commitment to delivering enduring value to our stakeholders."

 

  Conference Call Details  

 

The Company will host a conference call to discuss fourth quarter and year end results on Thursday, March 7, 2024 at 11:00 a.m. ET.

 

Interested parties may participate in the call by dialing:

 

877-407-6176 (US Toll-Free)
+1-201-689-8451 (International)

 

Live Audio Webcast: https://event.choruscall.com/mediaframe/webcast.html?webcastid=Axpi0DDw  

 

Following the conclusion of the call, an audio recording and transcript of the call can be accessed on the Company's website.

 

  ABOUT Viemed Healthcare, INC.  

 

Viemed is a provider of in-home medical equipment and post-acute respiratory healthcare services in the United States. Viemed's service offerings are focused on effective in-home treatment with clinical practitioners providing therapy and counseling to patients in their homes using cutting-edge technology. Visit our website at www.viemed.com.

 

For further information, please contact:

 

Glen Akselrod
Bristol Capital
905-326-1888
glen@bristolir.com

 

Todd Zehnder
Chief Operating Officer
Viemed Healthcare, Inc.
337-504-3802
investorinfo@viemed.com

 

   Forward-Looking Statements   

 

  Certain statements contained in this press release may constitute "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 or "forward-looking information" as such term is defined in applicable Canadian securities legislation (collectively, "forward-looking statements"). Often, but not always, forward-looking statements can be identified by the use of words such as "plans", "expects", "is expected", "budget", "potential", "scheduled", "estimates", "forecasts", "intends", "anticipates", "believes", "projects", or the negatives thereof or variations of such words and phrases or statements that certain actions, events or results "will", "should", "may", "could", "would", "might" or "will be taken", "occur" or "be achieved" or the negative of these terms or comparable terminology. All statements other than statements of historical fact, including those that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance, including the Company's net revenue guidance for the first quarter, are not historical facts and may be forward-looking statements and may involve estimates, assumptions and uncertainties that could cause actual results or outcomes to differ materially from those expressed in the forward-looking statements. Such statements reflect the Company's current views and intentions with respect to future events, and current information available to the Company, and are subject to certain risks, uncertainties and assumptions. Many factors could cause the actual results, performance or achievements that may be expressed or implied by such forward-looking statements to vary from those described herein should one or more of these risks or uncertainties materialize. These factors include, without limitation: the general business, market and economic conditions in the regions in which the Company operates; significant capital requirements and operating risks that the Company may be subject to; the ability of the Company to implement business strategies and pursue business opportunities; volatility in the market price of the Company's common shares; the state of the capital markets; the availability of funds and resources to pursue operations; inflation; reductions in reimbursement rates and audits of reimbursement claims by various governmental and private payor entities; dependence on few payors; possible new drug discoveries; dependence on key suppliers; granting of permits and licenses in a highly regulated business; competition; disruptions in or attacks (including cyber-attacks) on the Company's information technology, internet, network access or other voice or data communications systems or services; the evolution of various types of fraud or other criminal behavior to which the Company is exposed; difficulty integrating newly acquired businesses; the impact of new and changes to, or application of, current laws and regulations; the overall difficult litigation and regulatory environment; increased competition; increased funding costs and market volatility due to market illiquidity and competition for funding; critical accounting estimates and changes to accounting standards, policies, and methods used by the Company; the Company's status as an emerging growth company and a smaller reporting company; and the occurrence of natural and unnatural catastrophic events or health epidemics or concerns, and claims resulting from such events or concerns; as well as those risk factors discussed or referred to in the Company's disclosure documents filed with the U.S. Securities and Exchange Commission (the "SEC") available on the SEC's website at www.sec.gov, including the Company's most recent Annual Report on Form 10-K, and with the securities regulatory authorities in certain provinces of Canada available at www.sedar.com . Should any factor affect the Company in an unexpected manner, or should assumptions underlying the forward-looking statements prove incorrect, the actual results or events may differ materially from the results or events predicted. Any such forward-looking statements are expressly qualified in their entirety by this cautionary statement. Moreover, the Company does not assume responsibility for the accuracy or completeness of such forward-looking statements. The forward-looking statements included in this press release are made as of the date of this press release and the Company undertakes no obligation to publicly update or revise any forward-looking statements, other than as required by applicable law.  

 

  Use of Non-GAAP Financial Measures  

 

  This press release refers to Adjusted EBITDA and Free Cash Flow, which are financial measures that are not prepared in accordance with generally accepted accounting principles in the United States ("GAAP"). Adjusted EBITDA and Free Cash Flow should be considered in addition to, not as a substitute for, or superior to, financial measures calculated in accordance with U.S. GAAP.  

 

  Management believes Adjusted EBITDA provides helpful information with respect to the Company's operating performance as viewed by management, including a view of the Company's business that is not dependent on the impact of the Company's capitalization structure and items that are not part of the Company's day-to-day operations. Management uses Adjusted EBITDA (i) to compare the Company's operating performance on a consistent basis, (ii) to calculate incentive compensation for the Company's employees, (iii) for planning purposes, including the preparation of the Company's internal annual operating budget, and (iv) to evaluate the performance and effectiveness of the Company's operational strategies. Accordingly, management believes that Adjusted EBITDA provides useful information in understanding and evaluating the Company's operating performance in the same manner as management. Adjusted EBITDA is not a measurement of the Company's financial performance under U.S. GAAP and should not be considered as an alternative to revenue or net income, as applicable, or any other performance measures derived in accordance with U.S. GAAP and may not be comparable to other similarly titled measures of other businesses. Adjusted EBITDA has limitations as an analytical tool and you should not consider it in isolation or as a substitute for analysis of the Company's operating results as reported under U.S. GAAP. Adjusted EBITDA does not reflect the impact of certain cash charges resulting from matters the Company considers not to be indicative of ongoing operations; and other companies in the Company's industry may calculate Adjusted EBITDA differently than we do, limiting its usefulness as a comparative measure.  

 

  The Company uses Free Cash Flow in its operational and financial decision-making and believes free cash flow is useful to investors because similar measures are frequently used by securities analysts, investors, ratings agencies and other interested parties to evaluate the Company's competitors and to measure the ability of companies to service their debt. The Company's presentation of Free Cash Flow should not be construed as a measure of liquidity or discretionary cash available to the Company to fund its cash needs, including investing in the growth of its business and meeting its obligations.  

 

 

 
                                                                                                                                                                                                                                                                                                                           
  Viemed Healthcare, INC.  
CONSOLIDATED BALANCE SHEETS  
  (Expressed in thousands of U.S. Dollars, except share amounts)
 
 
    At  
December 31, 2023  
   At  
December 31, 2022  
  ASSETS      
  Current assets      
Cash and cash equivalents   $ 12,839   $ 16,914
Accounts receivable, net    18,451    15,379
Inventory    4,628    3,574
Income tax receivable      26
Prepaid expenses and other assets    2,449    3,849
  Total current assets    $ 38,367   $ 39,742
  Long-term assets      
Property and equipment, net    73,579    67,743
Finance lease right-of-use assets    401   
Operating lease right-of-use assets    2,872    694
Equity investments    1,680    2,155
Debt investment    2,219    2,000
Deferred tax asset    4,558    3,119
Identifiable intangibles, net    567   
Goodwill    29,765   
Other long-term assets    887    1,590
  Total long-term assets     116,528    77,301
  TOTAL ASSETS    $ 154,895   $ 117,043
     
  LIABILITIES      
  Current liabilities      
Trade payables   $ 4,180   $ 2,650
Deferred revenue    6,207    4,624
Income taxes payable    2,153   
Accrued liabilities    17,578    11,092
Finance lease liabilities, current portion    256   
Operating lease liabilities, current portion    678    495
Current debt    1,072   
  Total current liabilities    $ 32,124   $ 18,861
  Long-term liabilities      
Accrued liabilities    558    889
Finance lease liabilities, less current portion    132   
Operating lease liabilities, less current portion    2,184    199
Long-term debt    6,002   
  Total long-term liabilities    $ 8,876   $ 1,088
  TOTAL LIABILITIES    $ 41,000   $ 19,949
     
  Commitments and Contingencies      
     
  SHAREHOLDERS' EQUITY      
Common stock - No par value: unlimited authorized; 38,506,161 and 38,049,739 issued and outstanding as of December 31, 2023 and December 31, 2022, respectively    18,702    15,123
Additional paid-in capital    15,698    12,125
Retained earnings    79,495    69,846
  TOTAL SHAREHOLDERS' EQUITY    $ 113,895   $ 97,094
  TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY    $ 154,895   $ 117,043
 

 

 
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
  Viemed Healthcare, INC.  
CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME  
  (Expressed in thousands of U.S. Dollars, except outstanding shares and per share amounts)
 
 
   Three Months Ended
December 31,
 
   Year Ended
December 31,
 
    2023       2022       2023       2022   
  Revenue   $ 50,739    $ 37,508    $ 183,008    $ 138,832  
        
Cost of revenue   18,628     14,612     70,225     54,152  
        
  Gross profit   $ 32,111    $ 22,896    $ 112,783    $ 84,680  
        
  Operating expenses         
Selling, general and administrative   23,905     17,172     87,884     68,161  
Research and development   651     722     2,782     2,696  
Stock-based compensation   1,534     1,317     5,849     5,202  
Depreciation and amortization   434     241     1,391     1,012  
Loss on disposal of property and equipment   272     178     645     346  
Other income, net   26     (268 )    (98 )    (989 )
  Income from operations   $ 5,289    $ 3,534    $ 14,330    $ 8,252  
        
  Non-operating income and expenses         
Income from equity method investments   43     82     485     935  
Interest expense, net   (256 )    (32 )    (424 )    (197 )
        
  Net income before taxes    5,076     3,584     14,391     8,990  
Provision for income taxes   1,599     1,146     4,148     2,768  
        
  Net income   $ 3,477    $ 2,438    $ 10,243    $ 6,222  
        
  Other comprehensive income         
Change in unrealized gain/loss on derivative instruments, net of tax      (56 )       278  
  Other comprehensive income   $    $ (56 )   $    $ 278  
        
  Comprehensive income   $ 3,477    $ 2,382    $ 10,243    $ 6,500  
        
  Net income per share         
Basic $ 0.09    $ 0.06    $ 0.27    $ 0.16  
Diluted $ 0.09    $ 0.06    $ 0.25    $ 0.16  
        
  Weighted average number of common shares outstanding:         
Basic   38,492,731     38,015,795     38,354,071     38,655,403  
Diluted   40,383,109     39,513,158     40,378,922     39,807,434  
 

 

 
                                                                                                                                                                                                                                                                                                                                                                                                                                   
  Viemed Healthcare, INC.  
CONSOLIDATED STATEMENTS OF CASH FLOWS  
  (Expressed in thousands of U.S. Dollars)

 
 
    Year Ended December 31,  
     2023       2022   
  Cash flows from operating activities      
Net income   $ 10,243    $ 6,222  
Adjustments for:     
Depreciation and amortization    21,862     15,630  
Change in inventory reserve       (1,418 )
Stock-based compensation expense    5,849     5,202  
Distributions of earnings received from equity method investments    980     1,079  
Income from equity method investments    (485 )    (935 )
Income from debt investment    (219 )    
Loss on disposal of property and equipment    645     346  
Deferred income tax (benefit) expense    (1,439 )    1,746  
Changes in working capital, net of effects from acquisitions:     
Accounts receivable, net    (1,058 )    (2,556 )
Inventory    (472 )    301  
Prepaid expenses and other assets    2,176     (2,838 )
Trade payables    (859 )    (318 )
Deferred revenue    851     871  
Accrued liabilities    4,959     2,549  
Income tax payable/receivable    2,179     1,867  
  Net cash provided by operating activities    $ 45,212    $ 27,748  
     
  Cash flows from investing activities      
Purchase of property and equipment    (26,093 )    (22,898 )
Investment in equity investments    (20 )    (141 )
Cash paid for acquisition of HMP, net of cash acquired    (28,588 )    
Investment in debt security       (2,000 )
Proceeds from sale of property and equipment    2,588     1,063  
  Net cash used in investing activities    $ (52,113 )   $ (23,976 )
     
  Cash flows from financing activities      
Proceeds from exercise of options    1,303     283  
Proceeds from term notes    5,000     
Principal payments on term notes    (3,721 )    (5,796 )
Proceeds from revolving credit facilities    8,000     
Payments on revolving credit facilities    (7,005 )    
Shares redeemed to pay income tax    (594 )    (143 )
Shares repurchased under the share repurchase program       (9,568 )
Repayments of lease liabilities    (157 )    (42 )
  Net cash provided by (used in) financing activities    $ 2,826    $ (15,266 )
     
  Net decrease in cash and cash equivalents     (4,075 )    (11,494 )
  Cash and cash equivalents at beginning of year     16,914     28,408  
  Cash and cash equivalents at end of period    $ 12,839    $ 16,914  
     
  Supplemental disclosures of cash flow information      
Cash paid during the period for interest   $ 851    $ 231  
Cash paid (received) during the period for income taxes, net of refunds   $ 3,566    $ (846 )
  Supplemental disclosures of non-cash transactions      
Non-cash change in debt from the reclassification of debt issuance costs   $ (594 )   $  
Net non-cash changes to operating lease   $ (41 )   $ 530  
 

  
Non-GAAP Financial Measures
 

 

This press release refers to "Adjusted EBITDA" which is a non-GAAP financial measure that does not have a standardized meaning prescribed by U.S. GAAP. Adjusted EBITDA is defined as net income (loss) before net interest expense (income), income tax expense (benefit), depreciation and amortization, and stock-based compensation. Beginning with financial results reported for periods in fiscal year 2023, Adjusted EBITDA also excludes transaction costs and expenses related to acquisition and integration efforts associated with recently announced or completed acquisitions. This modification enables investors to compare period-over-period results on a more consistent basis without the effects of acquisitions. We have recast Adjusted EBITDA for prior periods when reported to conform to the modified presentation. The Company's presentation of this financial measure may not be comparable to similarly titled measures used by other companies.

 

The following table is a reconciliation of net income (loss), the most directly comparable U.S. GAAP measure, to Adjusted EBITDA, on a historical basis for the periods indicated:

 
                                                                                                                                                        
  
Viemed Healthcare, INC.
 
Reconciliation of Net Income to Non-GAAP Adjusted EBITDA  
  (Expressed in thousands of U.S. Dollars)   
  (Unaudited)  
  
 
  For the quarter ended    December 31,
2023
 
  September 30,
2023
 
  June 30,
2023
 
  March 31,
2023
 
  December 31,
2022
 
  September 30,
2022
 
  June 30,
2022
 
  March 31,
2022
 
  Net Income   $ 3,477 $ 2,919 $ 2,330   $ 1,517   $ 2,438 $ 1,055 $ 967 $ 1,762
Add back:         
Depreciation & amortization   5,918   5,975   5,207    4,762    4,373   4,120   3,740   3,397
Interest expense (income)   256   237   (20 )   (49 )   32   42   59   64
Stock-based compensation (a)   1,534   1,453   1,471    1,391    1,317   1,309   1,271   1,305
Transaction costs (b)   61   177   94    206      
Income tax expense   1,599   1,320   728    501    1,146   456   421   745
  Adjusted EBITDA    $    12,845    $    12,081    $    9,810     $    8,328     $    9,306    $    6,982    $    6,458    $    7,273  
 

(a) Represents non-cash, equity-based compensation expense associated with option and RSU awards.
(b) Represents transaction costs and expenses related to acquisition and integration efforts associated with recently announced or completed acquisitions.

 
                                  
    Year Ended
December 31, 2023
 
  Net Income    $ 10,243
Add back:   
Depreciation & amortization    21,862
Interest expense (income)    424
Stock-based compensation (a)    5,849
Transaction costs (b)    538
Income tax expense    4,148
  Adjusted EBITDA     $    43,064  
 

   
Free Cash Flow
 
 

 

This press release refers to "Free Cash Flow" which is a non-GAAP financial measure that does not have a standardized meaning prescribed by U.S. GAAP. Free Cash Flow is defined as net cash provided by operating activities less cash paid for purchases of property and equipment. The Company's presentation of this financial measure may not be comparable to similarly titled measures used by other companies.

 

The following unaudited table is a reconciliation of net cash provided by operating activities, the most directly comparable U.S. GAAP measure, to Free Cash Flow, on a historical basis for the periods indicated:

 
                                                                         
  (in thousands)     Three Months Ended
December 31,
 
   Year Ended
December 31,
 
     2023       2022       2023       2022   
Net cash provided by operating activities   $ 13,284    $ 7,684    $ 45,212    $ 27,748  
Purchase of property and equipment    (7,932 )    (5,572 )    (26,093 )    (22,898 )
  Free Cash Flow     $    5,352      $    2,112      $    19,119      $    4,850   
 

 

 
                                                                                                                                                                                                                                  
  Viemed Healthcare, INC.  
Key Financial and Operational Information  
  (Expressed in thousands of U.S. Dollars, except vent patients)   
  (Unaudited)  
  
 
  For the quarter ended    December 31,  
2023  
  September 30,
2023
 
  June 30,
2023
 
  March 31,
2023
 
  December 31,
2022
 
  September 30,
2022
 
  June 30,
2022
 
  March 31,
2022
 
  Financial Information:         
Revenue $ 50,739   $ 49,402   $ 43,311   $ 39,556   $ 37,508   $ 35,759   $ 33,310   $ 32,255  
Gross Profit   32,111    30,562    26,106    24,004    22,896    21,651    20,390    19,743  
Gross Profit %   63 %   62 %   60 %   61 %   61 %   61 %   61 %   61 %
Net Income   3,477    2,919    2,330    1,517    2,438    1,055    967    1,762  
Cash and Cash Equivalents (As of)   12,839    10,078    10,224    23,544    16,914    21,478    21,922    29,248  
Total Assets (As of)   154,895    149,400    149,117    124,634    117,043    119,419    115,904    119,007  
Adjusted EBITDA (1)   12,845    12,081    9,810    8,328    9,306    6,982    6,458    7,273  
  Operational Information:         
Vent Patients (2)   10,327    10,244    10,005    9,337    9,306    9,127    8,837    8,434  
 

  (1) Refer to "Non-GAAP Financial Measures" section above for definition of Adjusted EBITDA.
(2) Vent Patients represents the number of active ventilator patients on recurring billing service at the end of each calendar quarter.

 

 

 

  Primary Logo 

 

News Provided by GlobeNewswire via QuoteMedia

VMD
The Conversation (0)
Stardust Power Announces Year End 2024 Financial Results

Stardust Power Announces Year End 2024 Financial Results

 

Stardust Power Inc. ("Stardust Power" or the "Company") (Nasdaq: SDST), an American developer of battery-grade lithium products, today announced its results for the year ended December 31, 2024.

 

  Full Year Business Highlights  

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Stardust Power Announces Exclusive Licensing Agreement for Lithium Brine Concentration Technology from KMX Technologies

Stardust Power Announces Exclusive Licensing Agreement for Lithium Brine Concentration Technology from KMX Technologies

 
  •   Following the October 8, 2024 announcement, Stardust Power finalizes exclusive licensing agreement with KMX Technologies to enhance lithium production efficiency and sustainability.  
  •  

Stardust Power Inc. (NASDAQ: SDST) ("Stardust Power" or the "Company"), an American developer of battery-grade lithium products, today announced the execution of an exclusive licensing agreement with KMX Technologies, Inc. ("KMX"), a leader in advanced lithium brine concentration technology. This agreement grants Stardust Power the exclusive rights to utilize KMX's innovative vacuum membrane distillation ("VMD") technology for lithium extraction and concentration across the United States, Canada, and select international markets.

 

The exclusive license grants Stardust Power the full rights to use and operate KMX VMD units within the designated territory and field of use for lithium. This agreement will support Stardust Power's continued commitment to build out the North American lithium supply chain and onshoring of critical minerals in the rapidly growing North America lithium market.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Viemed Announces Acquisition of Majority Interest in HomeMed, Forging Partnership With East Alabama Health

 

Viemed Healthcare, Inc. (the "Company" or "Viemed") (NASDAQ:VMD), a national leader in respiratory care and technology-enabled home medical equipment services, announced the finalization of its strategic partnership with East Alabama Health ("EAH"), providing Viemed with the controlling interest of East Alabama HomeMed, LLC ("HomeMed"). HomeMed provides home medical equipment services to patients within the EAH network as well as those in the surrounding areas of Eastern Alabama.

 

"We are thrilled to join forces with the exceptional team at East Alabama Health to deliver best-in-class home medical services to their patients and expand HomeMed's business through the strategic partnership," said Viemed Chief Executive Officer Casey Hoyt. "This marks a significant milestone in our ongoing growth strategy, which includes hospital joint ventures and institutional partnerships. We view this transaction as a blueprint that can be replicated nationwide, enhancing care quality while simultaneously creating value for healthcare systems."

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Avrupa Minerals Ltd. 2023 Progress and 2024 Plans

Avrupa Minerals Ltd. 2023 Progress and 2024 Plans

 

(TheNewswire)

 
     
  Avrupa Minerals Ltd. 
          
 

 

News Provided by TheNewsWire via QuoteMedia

Keep reading...Show less
Actinogen

Actinogen confirms 100th participant in XanaMIA phase 2b/3 Alzheimer’s disease trial and interim analysis timeline

Actinogen Medical ASX: ACW (“ACW” or “the Company”) is pleased to announce that the 100th participant in its pivotal XanaMIA phase 2b/3 randomized trial of Xanamem® for Alzheimer’s disease (AD) has now passed all screening tests and is scheduled for randomization and treatment in July. This establishes the timeline for the planned safety and efficacy futility interim analysis by an independent Data Monitoring Committee (DMC).

Keep reading...Show less
Emyria Limited

Medibank to Fund Emyria’s PTSD Program at Perth Clinic

Emyria Limited (ASX: EMD) (“Emyria”, or the “Company”) a leader in developing and delivering innovative mental health treatments, is pleased to announce that Medibank Private Limited (“Medibank”), Australia’s largest private health insurer, has commenced funding for eligible customers to access Emyria’s Empax PTSD care program delivered in association with Perth Clinic.

Keep reading...Show less
ASX:HIQ

HITIQ Announces Exclusive Global Agreement with Shock Doctor for PROTEQT Instrumented Mouthguard

Common Shareholder Questions – Entitlement Offer

HITIQ Limited (ASX: HIQ) (HITIQ or the Company), a pioneer in concussion management, proudly announces an exclusive global agreement with Shock Doctor, the world’s leading mouthguard innovator. This landmark agreement marks Shock Doctor’s two-year effort to design a mouthguard that will integrate HITIQ’s PROTEQT technology. The result is a fully developed, market-ready solution that merges HITIQ’s smart sensor technology with Shock Doctor’s unmatched global production partner capabilities.

Keep reading...Show less
HeartSciences Inc

HeartSciences Receives FDA Breakthrough Device Designation for MyoVista Insights AI-ECG Algorithm for Detecting Aortic Stenosis

Aortic Stenosis is a Serious and Widespread Condition; The AI-ECG Algorithm Offers a Powerful Diagnostic Solution Designed for Seamless Integration with Hospital EHR Systems

Keep reading...Show less
Zoono Group

Exclusive UK Packaging Agreement signed between Sharpak Aylesham Limited, Zoono, and OSY

Zoono Group Limited (Company) (ASX: ZNO) is pleased to update the market on an exclusive contract signed with Sharpak Aylesham Limited (Sharpak) and the Company’s partner in the food supply chain sector, OSY Group Limited (OSY).

Keep reading...Show less
Amplia Therapeutics

Accent Trial Data Demonstrates that Narmafotinib + Chemotherapy Combination Superior to Chemotherapy Alone

Amplia Therapeutics Limited (ASX: ATX), (“Amplia” or the “Company”), is pleased to announce important new data from our ongoing ACCENT clinical trial in pancreatic cancer. The trial is investigating the Company’s best-in-class FAK inhibitor narmafotinib in combination with standard-of-care chemotherapies gemcitabine and Abraxane. Fifteen (15) confirmed partial responses (PRs) have now been recorded in the trial, a level of response sufficient to demonstrate that the combination of narmafotinib and chemotherapy is superior to chemotherapy alone.
Keep reading...Show less

Latest Press Releases

Related News

×